Unaudited financial results for the quarter ended September 30, 2025.
ABBOTINDIA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.4 pts more than Nifty Midcap 150 and 1.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Abbott India reported Q2 FY26 revenue from operations of Rs 1,757.15 Cr, up 7.6% YoY from Rs 1,632.67 Cr in Q2 FY25. Profit before tax rose to Rs 545.93 Cr from Rs 479.43 Cr, while profit after tax grew 15.8% to Rs 415.27 Cr from Rs 358.61 Cr. For the half year (H1 FY26), revenue stood at Rs 3,495.50 Cr (up 9.6%) and PAT at Rs 781.13 Cr (up 13.8%). EBITDA margins expanded meaningfully year-on-year, helped by controlled operating costs. The company paid dividends of Rs 1,009.34 Cr in H1 FY26 and generated Rs 521.94 Cr in operating cash flow. The statutory auditor's limited review report is clean with no qualifications.
PAT growing faster than revenue shows healthy operating leverage and margin expansion, which is positive for shareholders. Strong cash generation and large dividend payouts underscore robust shareholder returns; near-term stock reaction likely steady given consistent execution.